Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 30% ± 10% | |
peripheral blood | 17 studies | 31% ± 9% | |
intestine | 8 studies | 25% ± 9% | |
kidney | 5 studies | 28% ± 8% | |
lymph node | 5 studies | 29% ± 10% | |
brain | 5 studies | 29% ± 12% | |
bone marrow | 4 studies | 25% ± 4% | |
uterus | 4 studies | 39% ± 6% | |
breast | 4 studies | 31% ± 8% | |
liver | 4 studies | 24% ± 9% | |
adipose | 4 studies | 26% ± 6% | |
heart | 3 studies | 22% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 100% | 8263.15 | 1808 / 1809 | 99% | 254.00 | 466 / 472 |
lung | 100% | 9850.12 | 578 / 578 | 93% | 108.07 | 1075 / 1155 |
ovary | 100% | 6747.68 | 180 / 180 | 92% | 78.37 | 395 / 430 |
uterus | 100% | 8386.21 | 170 / 170 | 90% | 172.62 | 414 / 459 |
breast | 100% | 9682.43 | 459 / 459 | 90% | 58.80 | 1006 / 1118 |
esophagus | 99% | 5682.51 | 1433 / 1445 | 86% | 119.31 | 157 / 183 |
thymus | 99% | 5350.80 | 649 / 653 | 85% | 48.80 | 516 / 605 |
bladder | 95% | 5553.24 | 20 / 21 | 72% | 76.54 | 361 / 504 |
intestine | 99% | 5172.08 | 957 / 966 | 61% | 31.88 | 320 / 527 |
adrenal gland | 99% | 5306.07 | 256 / 258 | 57% | 21.68 | 131 / 230 |
kidney | 76% | 2698.47 | 68 / 89 | 77% | 50.68 | 698 / 901 |
stomach | 71% | 2406.14 | 255 / 359 | 66% | 35.36 | 189 / 286 |
prostate | 97% | 4279.23 | 237 / 245 | 39% | 11.97 | 197 / 502 |
brain | 30% | 754.53 | 796 / 2642 | 90% | 54.42 | 631 / 705 |
pancreas | 15% | 303.88 | 48 / 328 | 90% | 75.81 | 160 / 178 |
adipose | 100% | 12349.92 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 150.60 | 29 / 29 |
spleen | 100% | 11357.59 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 5986.69 | 1326 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 13988.68 | 916 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 208.73 | 44 / 45 |
heart | 87% | 2908.00 | 751 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 57% | 30.41 | 46 / 80 |
liver | 20% | 404.36 | 46 / 226 | 28% | 12.15 | 113 / 406 |
muscle | 34% | 785.62 | 270 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045814 | Biological process | negative regulation of gene expression, epigenetic |
GO_0042149 | Biological process | cellular response to glucose starvation |
GO_0045071 | Biological process | negative regulation of viral genome replication |
GO_0006954 | Biological process | inflammatory response |
GO_2000117 | Biological process | negative regulation of cysteine-type endopeptidase activity |
GO_0045087 | Biological process | innate immune response |
GO_0051607 | Biological process | defense response to virus |
GO_0042771 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0097202 | Biological process | activation of cysteine-type endopeptidase activity |
GO_0035458 | Biological process | cellular response to interferon-beta |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0045824 | Biological process | negative regulation of innate immune response |
GO_0010506 | Biological process | regulation of autophagy |
GO_0030099 | Biological process | myeloid cell differentiation |
GO_0072332 | Biological process | intrinsic apoptotic signaling pathway by p53 class mediator |
GO_0043392 | Biological process | negative regulation of DNA binding |
GO_0002218 | Biological process | activation of innate immune response |
GO_0006914 | Biological process | autophagy |
GO_0001819 | Biological process | positive regulation of cytokine production |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0030224 | Biological process | monocyte differentiation |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0016020 | Cellular component | membrane |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0008134 | Molecular function | transcription factor binding |
GO_0003690 | Molecular function | double-stranded DNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | IFI16 |
Protein name | Interferon gamma inducible protein 16 Gamma-interferon-inducible protein 16 (Ifi-16) (Interferon-inducible myeloid differentiation transcriptional activator) |
Synonyms | IFNGIP1 |
Description | FUNCTION: Binds double-stranded DNA. Binds preferentially to supercoiled DNA and cruciform DNA structures. Seems to be involved in transcriptional regulation. May function as a transcriptional repressor. Could have a role in the regulation of hematopoietic differentiation through activation of unknown target genes. Controls cellular proliferation by modulating the functions of cell cycle regulatory factors including p53/TP53 and the retinoblastoma protein. May be involved in TP53-mediated transcriptional activation by enhancing TP53 sequence-specific DNA binding and modulating TP53 phosphorylation status. Seems to be involved in energy-level-dependent activation of the ATM/ AMPK/TP53 pathway coupled to regulation of autophagy. May be involved in regulation of TP53-mediated cell death also involving BRCA1. May be involved in the senescence of prostate epithelial cells. Involved in innate immune response by recognizing viral dsDNA in the cytosol and probably in the nucleus. After binding to viral DNA in the cytoplasm recruits TMEM173/STING and mediates the induction of IFN-beta. Has anti-inflammatory activity and inhibits the activation of the AIM2 inflammasome, probably via association with AIM2. Proposed to bind viral DNA in the nucleus, such as of Kaposi's sarcoma-associated herpesvirus, and to induce the formation of nuclear caspase-1-activating inflammasome formation via association with PYCARD. Inhibits replication of herpesviruses such as human cytomegalovirus (HCMV) probably by interfering with promoter recruitment of members of the Sp1 family of transcription factors. Necessary to activate the IRF3 signaling cascade during human herpes simplex virus 1 (HHV-1) infection and promotes the assembly of heterochromatin on herpesviral DNA and inhibition of viral immediate-early gene expression and replication. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. .; FUNCTION: [Isoform IFI16-beta]: Isoform that specifically inhibits the AIM2 inflammasome . Binds double-stranded DNA (dsDNA) in the cytoplasm, impeding its detection by AIM2 . Also prevents the interaction between AIM2 and PYCARD/ASC via its interaction with AIM2, thereby inhibiting assembly of the AIM2 inflammasome . This isoform also weakly induce production of type I interferon-beta (IFNB1) via its interaction with STING1 . . |
Accessions | Q16666 H3BR65 H3BR88 ENST00000474473.1 ENST00000295809.12 [Q16666-1] X6RHM1 ENST00000368132.7 [Q16666-2] ENST00000566111.5 ENST00000447473.6 H3BM18 ENST00000426592.6 H3BVE6 ENST00000567661.5 ENST00000359709.7 [Q16666-6] ENST00000368131.8 [Q16666-2] ENST00000448393.6 [Q16666-3] |